Stéphane Bancel’s Post

Today marks a monumental day for Moderna as we officially celebrate the opening of our state-of-the-art global headquarters in Cambridge, Massachusetts! This new space serves as a central hub, fostering connections among our employees and the community. 🎉🍾 Our cutting-edge 460,000-square-foot facility showcases our dedication to science, sustainability, and innovation – and is designed with exceptional energy efficiency, featuring everything from solar panels to geothermal wells. We were thrilled to have Governor Healey, Lt. Gov. Driscoll and many other distinguished leaders, partners, and community members from across the state join us for the ribbon-cutting ceremony alongside #TeamModerna. Join us in celebrating this milestone!

As we advance our platform and continue to make progress in profoundly impacting human #health, we recognize that building the best version of Moderna requires increasing trust with stakeholders, protecting the health of the planet, and deeply caring for our employees and communities. Learn more about the progress we’ve made over the last few years in our third annual Environmental, Social and Governance (ESG) Report – a milestone that underscores our commitment to transparency, stakeholder engagement and integrating #ESG priorities into the heart of our operations. https://lnkd.in/gvvyJR_P

We announced today that our Phase 3 trial of mRNA-1083, an investigational combination #vaccine against #influenza and #COVID19, has met its primary endpoints. mRNA-1083 comprises components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate. Read more: https://lnkd.in/eiDqew4X

We recently published our inaugural annual #COVID19 report, which provides an overview of the evolving landscape of COVID-19, and discusses its comparative burden of disease as compared to influenza (flu).   With the continued evolution of the virus, and potential for more virulent variants, the reports explores potential barriers to and solutions for improving COVID-19 protection for future seasons.    Read more about the report here: https://lnkd.in/gzRNsiiS

We’re excited about the approval of mRESVIA® (Respiratory Syncytial Virus Vaccine) in the United States. With the approval of mRESVIA, Moderna is the first and only company in the world with two FDA-approved #mRNA #vaccine products. It is an exciting time for this new generation of vaccines and our platform’s continued impact on human health. Read more from our CEO Stéphane Bancel about this approval, and what’s next: https://lnkd.in/eHyp4KCR

Four years on, #COVID19 remains a worse killer than Flu. A new US study published in JAMA showed that last winter, patients hospitalized for COVID had a 35% higher risk of dying within 30 days than influenza patients. Learn more about the study's findings: https://lnkd.in/eF4gMP8t

In our latest #IRInsights video, members of our executive team sat down to recap this morning’s earnings report for the first quarter of 2024, and provide more insight into upcoming pipeline milestones, and exciting clinical and corporate developments happening at Moderna. Watch the full video: https://lnkd.in/gPwV4iyK

We’re excited to announce our ongoing collaboration with OpenAI to co-innovate with a shared vision of AI’s immense potential in the future of business and healthcare. #AI and collaborations like this will be a key component to our ability to scale and maximize our impact on patients. Watch the video below and read our blog to learn more about our work with #OpenAI: https://lnkd.in/eJ6wTcH2

Over the past four years, Theo has contracted #COVID19 a total of three times, and each case has been mild. It's what happens in the weeks and months after the COVID-19 diagnosis that he says has impacted his normal life. Theo's story is a stark reminder that #LongCOVID can affect anyone, regardless of age, and can have lasting impacts well beyond the initial infection. Read more about his battle with Long COVID: https://lnkd.in/emzSjaH7